Top Regional Bank Companies To Watch For 2015

I went out on a limb last week, and now it's time to see how that decision played out.

I predicted that People's United Financial (NASDAQ: PBCT  ) would close higher on the week. The regional banker had come up short on the bottom line in its two previous quarters, and the prior week closed with uninspiring earnings news out of the banking behemoths. People's United managed to match expectations on an operating basis, but the market was skeptical of financial services institutions this week. People's United Financial shares closed lower on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market was rocked hard this week, and secondary stocks led the way down. The Nasdaq fell 2.7% on the week. The Dow managed to close just 2.1% lower. I was wrong. My final call was for United Rentals (NYSE: URI  ) to beat Wall Street's quarterly profit target. The provider of equipment rentals with 836 outlets across the country has been beating Wall Street estimates consistently over the past year. Why should that end? Analysts were looking for a profit of $0.47 a share during the quarter, and it came through with adjusted net income of $0.58. I was right.

Two out of three? I can do better than that.

Top Regional Bank Companies To Watch For 2015: Zalicus Inc.(ZLCS)

Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of drug candidates focusing on the treatment of pain and inflammation. The company?s clinical and preclinical product candidates for pain and inflammatory diseases include Synavive, a glucocorticoid product candidate, which is in Phase 2b clinical development for the treatment of rheumatoid arthritis; Z160, an N-type calcium channel blocker for chronic pain; Z944, a T-type calcium channel blocker to treat acute or chronic inflammatory pain; and N-type and T-type calcium and sodium channel blockers for the treatment of chronic pain. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and Amgen Inc; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as C ombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Bryan Murphy]

  It's fun to be right, especially when it comes to picking stocks. Sometimes though, you can be a little too right, too fast, forcing a change in the game plan. Well, the good news/bad news is, I was too right, too fast with Zalicus Inc. (NASDAQ:ZLCS). Back on August 30th I pegged ZLCS as a buy-worthy trade, when it was trading at $0.71. It hit a peak of $0.93. That's a move of 31% in just two trading days. Though the gain has since been whittled down to 'only' 17% thanks to the retreat to the current price of $0.834, shares are still overbought, and I still have to advocate selling your short-term trade on the position.

• [By John Udovich]

  Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.

• [By Roberto Pedone]

  One biopharmaceutical player that's quickly moving within range of triggering a major breakout trade is Zalicus (ZLCS), which discovers and develops treatments for patients suffering from pain and immuno-inflammatory diseases. This stock has been destroyed by the bears over the last three months, with shares down by a whopping 81%.

  If you take a look at the chart for Zalicus, you'll notice that this stock gapped down sharply lower during last November, with shares falling from $4.83 to under $1.50 a share with heavy downside volume. Following that gap down, shares of ZLCS have tag a new low of 88 cents per share. This stock has now started to trend sideways over the last few weeks, with shares moving between $1.05 on the downside and $1.43 on the upside. Shares of ZLCS are spiking sharply higher today and taking out some near-term overhead resistance at $1.22 a share. That move is quickly pushing this stock within range of triggering a major breakout trade.

  Traders should now look for long-biased trades in ZLCS if it manages to break out above some near-term overhead resistance levels at $1.22 to $1.43 a share, and then once it clears its gap down day high of $1.45 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.70 million shares. If that breakout hits soon, then ZLCS will set up to re-fill some of its previous gap down zone from last November that started at $4.83 a share. This stock could easily hit $2 to $2.50 a share if it gets into that gap with volume.

  Traders can look to buy ZLCS off any weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support at $1.05 a share. One can also buy ZLCS off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Bryan Murphy]

  Against my better judgment, I'm going to go ahead and chime in on Zalicus Inc. (NASDAQ:ZLCS) again today. I say it's against my better judgment, because the last two times I opined about the near-term future of ZLCS, I caught some flack (despite the fact that the two takes were diametrical opposites of one another). So, I'm sure some members of at least one of those groups is still lingering out there, ready to pounce when I suggest something that doesn't jive with their views on Zalicus. That's ok though. Opposing viewpoints are how we broaden our horizon.

Top Regional Bank Companies To Watch For 2015: Orange County Business Bank (OCBB)

Orange County Business Bank is Orange County's elite full-service commercial bank. The Company is a capitalized bank in Southern California.

The Company is serving the needs of businesses and professionals throughout Orange County. It offers relationship banking services for locally owned and operated businesses, professional practices, and commercial/industrial companies in Orange County and adjacent markets.

Advisors' Opinion:

• [By CRWE]

  Today, OCBB remains (0.00%) +0.000 at $7.15 thus far (ref. google finance Delayed: 2:07PM EDT August 1, 2013).

  Orange County Business Bank previously reported financial results for the three months and six months ended June 30, 2013.

  The Bank�� net income for the three months ended June 30, 2013 was $204 thousand versus a net loss of $47 thousand for the same period in 2012. The Bank reported net income for the first six months of 2013 of $649 thousand versus a net loss of $126 thousand for the same period in 2012.

  The Bank�� net interest income for the three months ended June 30, 2013 was $1.4 million versus $1.1 million a year ago. The difference of $300 thousand in net interest income was primarily driven by an increase in the total loans outstanding. Net interest income for the six months ended June 30, 2013 was $2.6 million versus $2.4 million for the same period in 2012. The difference of $200 thousand was due to an increase in the total loans outstanding. The Bank continues to aggressively push into established and successful markets to develop profitable relationships. This push has resulted in the growth of loans, deposits and net interest income

Top Canadian Stocks To Buy Right Now: Intuitive Surgical Inc.(ISRG)

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems for various surgical procedures, including urologic, gynecologic, cardiothoracic, general, and head and neck surgeries. Its da Vinci surgical system consists of a surgeon?s console or consoles, a patient-side cart, a 3-D vision system, and proprietary ?wristed? instruments. The company?s da Vinci surgical system translates the surgeon?s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments positioned inside the patient through small puncture incisions, or ports. It also manufactures a range of EndoWrist instruments, which incorporate wrist joints for natural dexterity for various surgical procedures. Its EndoWrist instruments consist of forceps, scissors, electrocautery, scalpels, and other surgical tools. In addition, it sells various vision and accessory products for use in conjunction with the da Vinci Surgical System as surgical procedures are performed. The company?s accessory products include sterile drapes used to ensure a sterile field during surgery; vision products, such as replacement 3-D stereo endoscopes, camera heads, light guides, and other items. It markets its products through sales representatives in the United States, and through sales representatives and distributors in international markets. The company was founded in 1995 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By Keith Speights]

  At least one medical-device maker actually had a good first quarter. Robotic surgical systems maker Intuitive Surgical (NASDAQ: ISRG  ) grew its revenue by more than 23% year over year. First-quarter revenue of $611 million beat what analysts were expecting by $30 million. And Intuitive was shackled with the same medical-device tax that all the other aforementioned companies bore.

• [By Dan Caplinger]

  Intuitive Surgical (NASDAQ: ISRG  ) will release its quarterly report on Thursday, but don't expect shareholders to be too excited about the report. Shares of the company recently traded at their lowest levels in nearly two years, and with ongoing controversy about the company's da Vinci robotic surgical systems, it's unclear whether Intuitive Surgical earnings can hold up to the pressure the stock is under right now.

• [By Lisa Levin]

  Intuitive Surgical (NASDAQ: ISRG) shares moved up 10.89% to $485.70. The volume of Intuitive Surgical shares traded was 617% higher than normal. Intuitive Surgical announced the FDA clearance and U.S. introduction of the new da Vinci Xi Surgical System.

• [By Steve Symington and Alison Southwick]

  On the heels of Intuitive Surgical's (NASDAQ: ISRG  ) recent warning about weak capital spending in the U.S., MAKO Surgical (NASDAQ: MAKO  ) investors are worried that their up-and-coming company may not be able to meet its already conservative guidance when it reports earnings later this month.

Top Regional Bank Companies To Watch For 2015: Opko Health Inc(OPK)

OPKO Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It provides a range of solutions, including molecular diagnostics tests, proprietary pharmaceuticals, and vaccines to diagnose, treat, and prevent neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company offers molecular diagnostic platform technology for the rapid identification of molecules or immunobiomarkers; Alzheimer?s test for Alzheimer?s diagnostic; and protein-based influenza vaccines to provide multi-season and multi-strain protection against various influenza virus strains, such as seasonal influenza strains, as well as global influenza pandemic strains which include swine flu, and avian flu. It also offers Oligonucleotide Therapeutics for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and oligosaccharide for asthma and chronic obstructive pulmonary diseases. In addition, the company provides Rolapitant, a potent and antagonist; neurokinin-1, which has completed Phase II clinical trials for prevention of chemotherapy induced nausea and vomiting, and post-operative induced nausea and vomiting; and SCH 900978 that has completed Phase II clinical trials for chronic cough. Further, it offers bevasiranib, a drug candidate for the treatment of Wet AMD; and develops Aquashunt, a shunt to be used in the treatment of glaucoma. Additionally, the company involves in the development, commercialization, and sale of ophthalmic diagnostic and imaging systems, and instrumentation products. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

Advisors' Opinion:

• [By Roberto Pedone]

  Another healthcare player that insiders are jumping into here is Opko Health (OPK), which is a multi-national pharmaceutical and diagnostics company. Insiders are buying this stock into big time strength, since shares are up 76% in 2013.

  Opko Health has a market cap of $3.4 billion and an enterprise value of $3.5 billion. This stock trades at a premium valuation, with a price-to-sales of 38.01 and a price-to-book at 4.01. Its estimated growth rate for this year is -218.2%. This is not a cash-rich company, since the total cash position on its balance sheet is $180.84 million and its total debt is $226.74 million.

  The CEO just bought 19,400 shares, or about $171,000 worth of stock, at $8.79 to $8.90 per share. The same CEO also just bought 13,000 shares, or about $117,000 worth of stock, at $8.99 to $9.04 per share.

  From a technical perspective, OPK is currently trending above its 200-day moving average and below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares falling from its high of $11.64 to its recent low of $8.17 a share. During that downtrend, shares of OPK have been making mostly lower highs and lower lows, which is bearish technical price action.

  If you're in the bull camp on OPK, then I would look for long-biased trades as long as this stock is trending above its 200-day at $8.31 or above more key support at $8.17, and then once it breaks out above some near-term overhead resistance at $9.20 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 5.53 million shares. If that breakout hits soon, then OPK will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day of $10.06 a share to $11.64 a share.

• [By Jake L'Ecuyer]

  Opko Health (NYSE: OPK) tumbled 2.65 percent to $8.80. Opko Health shares have surged 93.16% over the past 52 weeks.

  Textura Corporation (NYSE: TXTR) shares were down as well, falling 16.19 percent to $31.72 after Citron Research issued a scathing report on the company midway through the morning Thursday.

• [By James E. Brumley]

  Look out Roche Holding Ltd. (OTCMKTS:RHHBY), and Opko Health Inc. (NYSE:OPK) - you're on notice too. There's a new player in the human growth hormone arena, and it may have built the proverbial better mousetrap. Versartis Inc. (NASDAQ:VSAR) only went public in late March, but with the dust from that IPO settling, it's already becoming clear that VSAR - admittedly a one-trick pony - could pose a real threat to OPK and RHHBY... at least on the human growth hormone front.

• [By John Udovich]
  SafeStitch Medical Inc. A developer and marketer of�best in class disposable medical devices to advance minimally invasive surgery for hernia repair, treatment of obesity and other gastroesophageal disorders, small cap SafeStitch Medical has developed and obtained FDA approval to market the AMID Hernia Fixation Device (HFD) for both inguinal and ventral hernia repairs. SafeStitch Medical has a couple of people behind it who are also involved in OPKO Health (NYSE: OPK)���a NYSE company with a $2.5 billion market cap. Moreover, these and other insiders were heavy buyers of the stock during the last private placement. On Wednesday, sank 18.57% to $0.855 (SFES has a 52 week trading range of $0.21 to $1.49 a share) for a market cap of $52.75 million but the stock is up 288.6% since the start of the year after surging this summer, up 42.5% over the past year and down 64.4% over the past five years.�

Top Regional Bank Companies To Watch For 2015: Cabot Oil & Gas Corporation(COG)

Cabot Oil & Gas Corporation operates as an independent oil and gas company in the United States. The company engages in the development, exploitation, exploration, production, and marketing of natural gas, crude oil, and natural gas liquids. It holds reserves in north region comprising Appalachian and Rocky Mountains areas; and south region consisting of Anadarko basin with Texas and Louisiana areas. The company also transports, stores, gathers, and purchases natural gas for resale. As of December 31, 2010, it had proved reserves of approximately 2,761 billion cubic feet of natural gas equivalents. The company was founded in 1989 and is headquartered in Houston, Texas.

Advisors' Opinion:

• [By Lee Jackson]

  Cabot Oil & Gas Corp. (NYSE: COG) is a name that fits the bill at Merrill Lynch. The company’s mid-December operating update reaffirmed several issues the analysts believe position the shares for another strong year in 2014. Strong production and a long-term selling agreement with Pacific Coast Summit Energy were cited as big positives. The Merrill Lynch price target for the stock is $47. The Thomson/First Call estimate is $45. Cabot closed Monday at $38.57.

Top Regional Bank Companies To Watch For 2015: Sovereign Lithium Inc (SLCO)

Sovereign Lithium, Inc., formerly Great American Energy Inc., incorporated on February 22, 2007, is a mineral exploration and development company focused on supporting clean energy and clean technology industries. The Company is engaged in identifying, acquiring and developing mineral assets in the United States and surrounding countries. The Company�� portfolio of projects primarily targets lithium production with a sub-focus on rare earth elements (REE).

The Company�� project includes Big Smoky Valley lithium project and Bear Creek REE project. Big Smoky Valley lithium project is located in Esmeralda Country in Nevada. It represents 48 unpatented placer mining claims consisting of 7,680 acres (3,108 hectares) in and around Esmeralda Country, Nevada. Bear Creek REE project consists of 10 mining claims totaling 7,311 acres (2,959 hectares) in British Columbia, Canada.

Advisors' Opinion:

• [By John Udovich]

  Small cap OTC stocks Sovereign Lithium Inc (OTCMKTS: SLCO), Life Stem Genetics Inc (OTCMKTS: LIFS), Nevada Gold Corp (OTCMKTS: NVGC), Guar Global Ltd (OTCMKTS: GGBL) and Makism 3D Corp (OTCMKTS: MDDD) all saw their trading halted late last year by the SEC, but now all of these stocks are trading again. So what's going on and why the sudden crackdown? First, here is a quick look at what happened to the following five small cap stocks:

• [By James E. Brumley]

  Well, as it turns out, the snake that bit L&L Energy, Inc. (NASDAQ:LLEN) and Sovereign Lithium Inc. (OTCMKTS:SLCO) didn't end up biting Makism 3D Corp. (OTCMKTS:MDDD). And in retrospect, that's probably how it should be. Indeed, the fact that MDDD didn't even come close to suffering the same fate as SLCO or LLEN did may be the biggest assurance Makism 3D fans could hope for that the company is everything it says it is.

Top Regional Bank Companies To Watch For 2015: Imperva Inc (IMPV)

Imperva, Inc. (Imperva), incorporated on April 2002, is engaged in providing data security solutions focused on providing visibility and control over business data across systems within the data center. The Company�� securesphere data security suite is a solution designed to prioritize and mitigate risks to high-value business data, protect against hackers and malicious insiders and address and streamline regulatory compliance. SecureSphere is an integrated, modular suite, which provides database, file and Web application security and secures all business data across a range of systems in data centers, including traditional on-premise data centers as well as private, public and hybrid cloud computing environments. The Company also offers on-demand, cloud-based security services. The Company has two segments: Imperva, which is comprised of its financial position and results of operations and those of the Company�� wholly owned subsidiaries, and Incapsula, which is comprised of the financial position and results of operations of the Company�� majority owned subsidiary. In February 2014, Imperva Inc acquired real-time mainframe security auditing agents from Tomium Software.

The Company�� products include SecureSphere data security suite for enterprise data centers and its cloud-based security services that it provides through Incapsula for mid-market enterprises and small and medium business (SMBs). The Company�� solution includes database security, file security and Web application security.

Database Security

Database security provides full visibility and control over structured business data repositories, including database data usage, vulnerabilities and access rights and enables security, audit, risk and information technology (IT) professionals to improve data security and address compliance requirements. The database products cover the enterprise database platforms, including Oracle, MS-SQL, IBM DB2, Sybase, Informix, MySQL, Progress, Teradata and ! Netezza. The database security products include discovery and assessment server, database activity monitoring, database firewall, user rights management for databases and analog-to-digital converter (ADC) insights. The discovery and assessment server automates the process of discovering databases and other business data on the network and performs a security assessment to identify risks to high-value business data. Database activity monitoring includes all discovery and assessment server functionality. Database firewall includes database activity monitoring functionality. User rights management for databases enables the management of user rights across heterogeneous enterprise databases by aggregating user rights to illustrate what rights users have to business data. ADC Insights provides user tracking for identifying the real end user behind database transactions.

The Company competes with International Business Machines Corporation, McAfee, Inc. and Oracle Corporation.

File Security

File security provides full visibility and control over unstructured business data repositories, including file ownership, usage and access rights and enables security, audit, risk and information technology (IT) professionals to improve file data security and address compliance requirements. The file security products are designed to secure files, including spreadsheets, presentation slides, word processing documents and portable document format (PDFs) containing high-value business data that its customers store in unstructured repositories, such as file servers, network attached storage and storage area network devices. The File security products include user rights management for files, file activity monitoring and file firewall. User rights management for files enables the management of user access rights across multiple different file storage systems by aggregating user rights based on organizational context and actual file usage to illustrate what rights users have to sensitive ! files. Fi! le activity monitoring includes all user rights management for files functionality. File firewall includes all file activity monitoring functionality, and provides real-time blocking of suspicious activity that violates corporate policies.

The Company competes with EMC Corporation and Symantec Corporation.

Web Application Security

Web application security protects Web applications from large scale cyber attacks, adapts to evolving threats to prevent data breaches and addresses compliance requirements. Its product includes Web application firewall (WAF), which fortifies Web defenses with research-driven intelligence on current threats.

The Company competes with Citrix Systems, Inc. and F5 Networks, Inc.

Cloud-Based Services

The Company�� cloud-based service offerings are its Incapsula service, the Imperva Cloud WAF Service and its ThreatRadar subscription service. The Incapsula service is designed to be easy to deploy and to be accessible to small and medium size businesses that need data security and compliance solutions, but do not have the size or resources to deploy its SecureSphere WAF appliances into their own Website infrastructure. Incapsula�� security and optimization offerings include the services, including Web application firewall services, content delivery optimization and distributed denial of service-attack prevention. Web application firewall services provide enterprise-grade blocking of attacks against Web applications to help ensure Website safety and availability; enhanced security through real-time and centralized threat detection across all protected Websites; allows customers to address compliance requirements. Content delivery optimization optimizes Website performance by reducing page load times, server load and bandwidth consumption. Distributed denial of service-attack prevention blocks malicious attack traffic and allows filtered, legitimate traffic to flow to the customer Website allowing its b! usiness t! o run without interruption.

Imperva Cloud WAF powered by Incapsula, bundles the incapsula service with managed support services from our security operations center (SOC). Managed services include provisioning, security alert notifications and tuning, incident response, real time service dashboard and statistics, customer support and weekly reports on alerts and attack trends. ThreatRadar is an add-on, premium subscription service for the Company�� SecureSphere WAF appliance that recognizes attack sources and dynamically adjusts Web security policies within its SecureSphere WAF appliance to provide protection against them.

The customers include four of the telecommunications companies, three of the commercial banks in the United States, three of the financial data service firms, three of the computer hardware companies, two of the food and drug store companies, over 150 government agencies worldwide and more than 100 Fortune 1000 companies. The Company primarily sells its products and services through its network of over 350 channel partners worldwide, including both distributors and resellers. The Company derives its revenue from sales and licenses of its products and sales of its services. Services revenue consists of maintenance and support, professional services and training and subscriptions. A majority of the Company�� revenue is derived from customers in the Americas region. As of December 31, 2010, 66% of its total revenue was generated from the Americas, 24% from Europe, Middle East and Africa (EMEA) and 10% from Asia Pacific, and for the six months ended June 30, 2011, 63% of its total revenue was generated from the Americas, 24% from EMEA and 13% from Asia Pacific.

Advisors' Opinion:

• [By Monica Gerson]

  Imperva (NYSE: IMPV) shares tumbled 41.52% to touch a new 52-week low of $29.08 after the company cut its first-quarter outlook. Imperva now expected a loss of $0.40 to $0.44 per share, on revenue of $31 million to $31.5 million.

• [By Monica Gerson]

  Imperva (NYSE: IMPV) shares tumbled 37.68% to $30.99 after the company cut its first-quarter outlook. Imperva now expected a loss of $0.40 to $0.44 per share, on revenue of $31 million to $31.5 million.

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Imperva (NYSE: IMPV) were down 38.35 percent to $30.66 after the company cut its first-quarter outlook. Imperva now expected a loss of $0.40 to $0.44 per share, on revenue of $31 million to $31.5 million.

Top Regional Bank Companies To Watch For 2015: Auxilium Pharmaceuticals Inc.(AUXL)

Auxilium Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company primarily in the United States. It focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, and rheumatologists, as well as to orthopedic, general, and plastic surgeons. The company markets XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of adult Dupuytren?s contracture; and Testim, a topical 1% testosterone gel for the treatment of hypogonadism. The company?s clinical development products include XIAFLEX that is in Phase III clinical trials for the treatment of Peyronie?s disease, as well as in Phase II clinical trials for the treatment of Adhesive Capsulitis. In addition, it has rights to develop other products for the treatment of pain, urologic disease, and hormone replacement using its transmucosal film delivery system. The company has a strategic alliance with Asahi Kasei Ph arma Corporation for the development, commercialization, and supply of XIAFLEX, a biologic for the treatment of Dupuytren?s contracture and Peyronie?s disease. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.

Advisors' Opinion:

• [By Roberto Pedone]

  One potential earnings short-squeeze candidate is biotechnology player Auxilium Pharmaceuticals (AUXL), which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Auxilium Pharmaceuticals to report revenue of $91.43 million on a loss of 3 cents per share.

  During the last quarter, this company reported revenue of $66.2 million and GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million. Also during the last quarter, this company reported non-GAAP EPS of -12 cents per share and GAAP EPS of -17 cents per share.

  The current short interest as a percentage of the float for Auxilium Pharmaceuticals is pretty high at 11.1%. That means that out of the 39.84 million shares in the tradable float, 5.14 million shares are sold short by the bears. This is a decent short interest on a stock with a relatively low tradable float. If the bulls get the earnings news they're looking for, then shares of AUXL could easily rip higher post-earnings as the bears rush to cover some of their short bets.

  From a technical perspective, AUXL is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last three months, with shares soaring higher from its low of $13.87 to its intraday high of $18.42 a share. During that uptrend, shares of AUXL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of AUXL within range of triggering a major breakout trade post-earnings.

  If you're bullish on AUXL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some key overhead resistance levels at $18.50 to $19.60 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 834,059 shares. If that breakout hits, then AUXL will set up

• [By Sean Williams]

  Also, the testosterone market is also glutted with competition and Aveed, even will likely have a hard time making any meaningful impact for Endo. AbbVie (NYSE: ABBV  ) recently reformulated its AndroGel testosterone treatment into a more potent form at 1.62% and in 2011 received FDA approval after 82% of hypogonadal men achieved normal testosterone levels after 112 days. Also operating in the gel space is Auxilium Pharmaceuticals' (NASDAQ: AUXL  ) drug Testim, which achieved $45.5 million in sales in the first quarter. That figure actually represents a 23% year-over-year decline because of difficulties in gaining insurance coverage for the gel, but it's yet another hurdle for Aveed to jump over if it were to reach market.

• [By Jake L'Ecuyer]

  Auxilium Pharmaceuticals (NASDAQ: AUXL) was also up, gaining 12.11 percent to $21.67 following FDA approval of its Peyronie's disease treatment, Xiaflex.